

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

FERRING PHARMACEUTICALS INC.,)	
FERRING B.V., and FERRING)	
INTERNATIONAL CENTER S.A.,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 17-479 (GMS)
)	
SERENITY PHARMACEUTICALS, LLC,)	
REPRISE BIOPHARMACEUTICALS, LLC,)	
and ALLERGAN, INC.,)	
)	
Defendants.)	

DEFENDANTS SERENITY AND REPRISE’S MOTION TO DISMISS

Defendants Serenity Pharmaceuticals, LLC and Reprise Biopharmaceutics, LLC (“Reprise”) (collectively, “Defendants”) respectfully move for: (1) dismissal in its entirety of the Amended Complaint for Declaratory Judgment (the “Amended Complaint”) (D.I. 18), filed on June 30, 2017 by Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (collectively, “Plaintiffs”), pursuant to Fed. R. Civ. P. 12(b)(1), for lack of subject-matter jurisdiction; (2) dismissal of the Amended Complaint with respect to Defendant Reprise, the owner of U.S. Patent Nos. 7,405,203, 7,579,321, and 7,799,761, for lack of personal jurisdiction pursuant to Fed. R. Civ. P. 12(b)(2); (3) dismissal of Count V of the Amended Complaint, pursuant to Fed. R. Civ. P. 12(b)(6), for failure to state a claim upon which relief can be granted; and (4) an Order dismissing the Amended Complaint in its entirety under Fed. R. Civ. P. 15(d) for failure to seek leave of Court before filing a supplemental pleading.

Plaintiffs filed their original Complaint on April 28, 2017. (D.I. 1) On June 9, 2017, Defendants moved for: (1) dismissal of the Complaint pursuant to Fed. R. Civ. P. 12(b)(1), for lack of subject-matter jurisdiction; (2) dismissal of the Complaint with respect to Defendant

Reprise for lack of personal jurisdiction pursuant to Fed. R. Civ. P. 12(b)(2); (3) dismissal of Count V of the Complaint, pursuant to Fed. R. Civ. P. 12(b)(6), for failure to state a claim upon which relief can be granted. (D.I. 11) In the alternative, Defendants moved the Court to transfer the case to the Southern District of New York. Thereafter, on June 30, 2017, Plaintiffs filed their Amended Complaint (D.I. 18) and their Answering Brief in response to Defendants' June 9, 2017 Motion (D.I. 19), arguing that the motion to dismiss is moot in light of the Amended Complaint.

The grounds for this motion are fully set forth in Defendants' opening and reply briefs accompanying their Motion to Dismiss, Or In The Alternative, To Transfer, Plaintiffs' Complaint for Declaratory Judgment (*see* D.I. 12 and 23), which are incorporated herein by reference.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jack B. Blumenfeld

Jack B. Blumenfeld (#1014)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com

Attorneys for Defendants

OF COUNSEL:

Christopher J. Harnett
James Sottile IV
Shehla Wynne
JONES DAY
250 Vesey Street
New York, NY 10281
(212) 326-3939

*Attorneys for Serenity Pharmaceuticals, LLC
and Reprise Biopharmaceuticals, LLC*

July 14, 2017

CERTIFICATE OF SERVICE

I hereby certify that on July 14, 2017, copies of the foregoing were caused to be served upon the following in the manner indicated:

Mary W. Bourke, Esquire
Dana K. Severance, Esquire
Daniel Attaway, Esquire
WOMBLE CARLYLE SANDRIDGE & RICE, LLP
222 Delaware Avenue, Suite 1501
Wilmington, DE 19801
Attorneys for Plaintiffs

VIA ELECTRONIC MAIL

Keats A. Quinalty, Esquire
John W. Cox, Esquire
Joshua A. Davis, Esquire
WOMBLE CARLYLE SANDRIDGE & RICE, LLP
271 17th Street NW, Suite 2400
Atlanta, GA 30363
Attorneys for Plaintiffs

VIA ELECTRONIC MAIL

/s/ Jack B. Blumenfeld

Jack B. Blumenfeld (#1014)